# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Florence Griffith Joyner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML033-SYN-TD
- Date: 1996-05-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Vanterpool, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

EEG and MRI results and epilepsy consultation. **S**

## History of present illness

Ms. Griffith Joyner returns two weeks after her first visit. The sleep-deprived EEG two days after that visit showed intermittent left frontal sharp waves and slowing. MRI of the brain six days after the visit, with susceptibility-weighted imaging, shows a single 1.4 cm cavernous malformation in the left orbitofrontal cortex with a hemosiderin rim and an adjacent developmental venous anomaly, and no other lesion. Dr. Mehta-Sorensen of the epilepsy service saw her this morning. She has had no further seizure, spell or headache. She has not driven, showers rather than bathes, and has not swum. The records of her earlier seizure care have been requested and have not arrived. She is not pregnant (negative test at the first visit) and is not planning a pregnancy now. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| EEG | Left frontal sharp waves and focal slowing |
| MRI | Single 1.4 cm left orbitofrontal cavernous malformation with a hemosiderin rim; no other lesion on susceptibility-weighted imaging |
| Since the last visit | No seizure; not driving |
| Coordination | Epilepsy consultation today; neurosurgical opinion requested |
| Her questions | Whether this is epilepsy, whether the lesion can be removed, and when she can train and drive |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight change |
| Neurological | Negative | No seizures, spells, headache, weakness or change in smell or vision |
| Musculoskeletal | Negative | Muscle aches after the seizure have gone |
| Genitourinary | Negative | Regular periods; not pregnant |
| Psychiatric | Positive | Worried about another seizure in public; PHQ-9 3; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Folic acid 0.4 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/68 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 61.2 kg; BMI 21.2 kg/m². All vital signs are synthetic.

PHQ-9: 3. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Fit and well; weight 61.2 kg; blood pressure 110/68, pulse 58 |
| Neurological | Alert and oriented; smell intact to coffee in each nostril; cranial nerves, strength, reflexes, sensation, coordination and gait normal |
| Mouth | No tongue or mouth injury |
| Psychiatric | Composed and attentive; asks precise questions |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Focal epilepsy with structural cause from a left orbitofrontal cavernous malformation** (G40.209). The seizure was a focal to bilateral tonic-clonic seizure arising from the left orbitofrontal cortex, where the EEG shows epileptiform discharges and the MRI shows a cavernous malformation. Under the ILAE 1984 practical definition this is epilepsy after a single unprovoked seizure, because an epileptogenic lesion with matching EEG discharges carries a recurrence risk above 60%; her earlier seizures by history point the same way. Dr. Mehta-Sorensen recommends an antiseizure medication now and a neurosurgical opinion on lesionectomy. Levetiracetam is chosen for a woman who could become pregnant: low risk of birth defects, no interaction with hormonal contraception, and an effective dose from the first day; lamotrigine would need weeks of slow titration and its level falls with estrogen-containing contraception. Valproate is avoided because it carries the highest risk of major malformations and of lower intelligence in children exposed in pregnancy. Folic acid 0.4 mg daily. Levetiracetam can cause irritability or low mood, so mood is checked at each visit; baseline PHQ-9 is 3. **S**
   - Levetiracetam 500 mg twice daily from today.
   - Folic acid 0.4 mg daily.
   - Neurosurgical opinion on lesionectomy within three weeks.
   - Seizure diary; seizure action plan and first aid card.
   - Nocturnal seizure detection watch ordered.
   - Still no driving.
2. **Solitary cerebral cavernous malformation, left orbitofrontal** (Q28.3). A single lesion with a developmental venous anomaly and no other lesions on susceptibility-weighted imaging is the sporadic pattern, so genetic testing for familial cavernous malformation is not needed. No acute hemorrhage. Because it causes her epilepsy and lies in accessible cortex, removing it with its hemosiderin rim offers a good chance of freedom from seizures. **S**
   - Neurosurgery evaluation.
   - Report sudden severe headache, new weakness, numbness, speech or vision change at once.
3. **Generalized seizure on a flight** (R56.9). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count, electrolytes, glucose, calcium, magnesium, kidney and liver tests, creatine kinase, pregnancy test | At presentation after a seizure | Up to date | All normal at the first visit; pregnancy test negative |
| Imaging | EEG (sleep-deprived) | After a first seizure, as soon as practical | Up to date | Two days after the first visit: left frontal sharp waves and focal slowing |
| Imaging | MRI of the brain, epilepsy protocol with susceptibility-weighted imaging | After a first seizure | Up to date | Six days after the first visit: single left orbitofrontal cavernous malformation with a hemosiderin rim |
| Examination | Seizure classification and diagnosis of epilepsy | When EEG and imaging are available | Completed today | Focal to bilateral tonic-clonic seizure; focal epilepsy with structural cause (ILAE 1984: one unprovoked seizure with recurrence risk above 60%) |
| Referral | Neurology (epilepsy) | Within two weeks of a first seizure | Completed today | Seen this morning; recommendations in the consultation note |
| Referral | Neurosurgical evaluation of an epileptogenic cavernous malformation | When a cavernous malformation causes epilepsy | Ordered | Requested today, within three weeks |
| Medication safety | Antiseizure medication choice for a woman who could become pregnant | At the start of treatment | Completed today | Levetiracetam 500 mg twice daily; valproate avoided; no contraceptive interaction |
| Medication safety | Folic acid | Daily for anyone taking an antiseizure medication who could become pregnant | Completed today | 0.4 mg daily started |
| Self-management | Contraception and pregnancy planning | At the start of treatment and yearly | Completed today | No pregnancy planned; any method is compatible with levetiracetam; plan a pregnancy with the epilepsy team |
| Survey | Mood and behavior on levetiracetam (PHQ-9) | Before starting and at each visit | Completed today | PHQ-9 3 before the first dose |
| Self-management | Driving restriction and the California physician report | From the first seizure until cleared | Up to date | Not driving; the report California requires was sent after the first visit |
| Self-management | Seizure safety: water, heights, sleep and first aid | At diagnosis and each visit | Completed today | Showers only; swimming only with a companion who knows first aid; no climbing or working at height; written seizure action plan |
| Self-management | Nocturnal seizure detection | When seizures may occur in sleep | Ordered | Wrist-worn detection watch ordered |
| Self-management | SUDEP counseling | At diagnosis of epilepsy | Deferred | Not discussed today: the visit was taken up by the diagnosis, the medication and the surgical question. A deviation from the AAN/AES guideline, which calls for the discussion at diagnosis. Corrective action: booked as the first item at the next visit in three weeks |

## Goal progress

- EEG and MRI with susceptibility-weighted imaging within one week, and an epilepsy consultation within two weeks. Outcome by 1996-05-05: EEG in two days, MRI in six, consultation at two weeks. **S**
- No further seizures on an antiseizure medication she tolerates. In progress; target 1996-10-20. **S**
- Neurosurgical evaluation of the cavernous malformation and a shared decision about lesionectomy within two months. In progress; target 1996-07-21. **S**
- Safety plan in place: no driving until cleared, water and height safety, SUDEP discussion, and a nocturnal seizure detection plan. In progress; target 1996-05-27. **S**
- Graded return to full sprint training within four months of surgery. In progress; target 1996-10-20. **S**

## Medication changes

- Started: Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Started: Folic acid 0.4 mg oral tablet, one tablet daily **S**

## Guideline basis

- Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705-1713 (PMID 25901057) (2015), American Academy of Neurology and American Epilepsy Society
- Fisher RS, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-482 (PMID 24730690) (2014), International League Against Epilepsy
- Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665-680 (PMID 28387823) (2017), Angioma Alliance (Neurosurgery)
- Harden C, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology 2017;88(17):1674-1680 (PMID 28438841) (2017), American Academy of Neurology and American Epilepsy Society
- Pack AM, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology 2024;102(11):e209279 (PMID 38748979) (2024), American Academy of Neurology, American Epilepsy Society and Society for Maternal-Fetal Medicine
- Beniczky S, et al. Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia 2021;62(3):632-646 (PMID 33666944) (2021), International League Against Epilepsy and International Federation of Clinical Neurophysiology
- Governor's message returning Senate Bill 357 without signature (physician reporting of disorders characterized by lapses of consciousness remains mandatory under Health and Safety Code section 103900) (2024), Office of the Governor of California
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Neurosurgical opinion within three weeks; primary care review in three weeks to check levetiracetam, mood and the surgical plan, and to discuss SUDEP. Call at once for another seizure; call emergency services for a seizure lasting five minutes or more. **S**
- Next scheduled visit 1996-05-27: three weeks on levetiracetam: mood and side effects, the neurosurgical opinion and surgery date, SUDEP and safety counseling. **S**
